1,278
Views
22
CrossRef citations to date
0
Altmetric
Original Research

Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study

, , , &
Pages 1653-1659 | Published online: 15 Nov 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Satoshi Soen, Saeko Fujiwara, Ryoichi Takayanagi, Kenta Kajimoto, Mika Tsujimoto, Shuichi Kimura, Masayo Sato, John H. Krege & Hiroyuki Enomoto. (2017) Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS). Current Medical Research and Opinion 33:11, pages 2049-2056.
Read now

Articles from other publishers (21)

Marian Schini, Tatiane Vilaca, Fatma Gossiel, Syazrah Salam & Richard Eastell. (2023) Bone Turnover Markers: Basic Biology to Clinical Applications. Endocrine Reviews 44:3, pages 417-473.
Crossref
Rose M. Ayoob & John D. Mahan. (2022) Pediatric CKD-MBD: existing and emerging treatment approaches. Pediatric Nephrology 37:11, pages 2599-2614.
Crossref
John H Krege, Alicia W Gilsenan, John L Komacko & Nicole Kellier‐Steele. (2022) Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates. JBMR Plus 6:9.
Crossref
Paul D Miller, Jonathan D Adachi, Ben‐Hur Albergaria, Angela M Cheung, Arkadi A Chines, Evelien Gielen, Bente L Langdahl, Akimitsu Miyauchi, Mary Oates, Ian R Reid, Norma Ruiz Santiago, Mark Vanderkelen, Zhenxun Wang & Zhigang Yu. (2022) Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease . Journal of Bone and Mineral Research 37:8, pages 1437-1445.
Crossref
Bo Li, Yu Wang, Shiqiang Gong, Weifan Yao, Hua Gao, Mingyan Liu & Minjie Wei. (2022) Puerarin improves OVX-induced osteoporosis by regulating phospholipid metabolism and biosynthesis of unsaturated fatty acids based on serum metabolomics. Phytomedicine 102, pages 154198.
Crossref
A. K. Eremkina, A. M. Gorbacheva, V. A. Enenko, E. E. Litvinova & N. G. Mokrysheva. (2022) Experience in using teriparatide for the treatment of postoperative hypoparathyroidism in hemodialysis patients. Problems of Endocrinology 68:4, pages 30-39.
Crossref
Geeta Hampson, Grahame J. Elder, Martine Cohen-Solal & Bo Abrahamsen. (2021) A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease. Endocrine 73:3, pages 509-529.
Crossref
Iacopo Chiodini, Agostino Gaudio, Andrea Palermo, Nicola Napoli, Fabio Vescini, Alberto Falchetti, Daniela Merlotti, Cristina Eller-Vainicher, Vincenzo Carnevale, Alfredo Scillitani, Giuseppe Pugliese, Domenico Rendina, Antonio Salcuni, Francesco Bertoldo, Stefano Gonnelli, Ranuccio Nuti, Vincenzo Toscano, Vincenzo Triggiani, Simone Cenci & Luigi Gennari. (2021) Management of bone fragility in type 2 diabetes: Perspective from an interdisciplinary expert panel. Nutrition, Metabolism and Cardiovascular Diseases 31:8, pages 2210-2233.
Crossref
Kirstin Kusumi, Ala Shaikhkhalil, Hiren P. Patel & John D. Mahan. (2020) Promoting bone health in children and adolescents following solid organ transplantation. Pediatric Transplantation 25:1.
Crossref
Kamyar Asadipooya, Mohamed Abdalbary, Yahya Ahmad, Elijah Kakani, Marie-Claude Monier-Faugere & Amr El-Husseini. (2021) Bone Quality in Chronic Kidney Disease Patients: Current Concepts and Future Directions – Part II. Kidney Diseases 7:5, pages 359-371.
Crossref
Pieter Evenepoel, John Cunningham, Serge Ferrari, Mathias Haarhaus, Muhammad Kassim Javaid, Marie-Hélène Lafage-Proust, Daniel Prieto-Alhambra, Pablo Ureña Torres, Jorge Cannata-Andia, Marc Vervloet, Sandro Mazzaferro, Patrick D’Haese, Justine Bacchetta, Annibal Ferreira, Syazrah Salam & Goce Spasovski. (2021) European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D. Nephrology Dialysis Transplantation 36:1, pages 42-59.
Crossref
Yevgeniya Kushchayeva & E. Michael Lewiecki. 2021. Image Guided Interventions of the Spine. Image Guided Interventions of the Spine 61 92 .
Michael Pazianas & Paul D Miller. (2020) The CKD‐MBD Syndrome: Hysteresis in PTH Involvement and PTH Administration for Its Management . Journal of Bone and Mineral Research 35:12, pages 2313-2317.
Crossref
Feng-Chen Kao, Yao-Chun Hsu, Tzu-Shan Chen, Yuan-Kun Tu & Pao-Hsin Liu. (2020) Effects of Injected Antiosteoporotic Medication Versus Oral Bisphosphonates on Rates of Repeated Vertebroplasty or Kyphoplasty. Clinical Therapeutics 42:6, pages 1087-1098.e2.
Crossref
Michael Pazianas & Paul Dennis Miller. (2020) Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease and the Scientific Grounds on the Use of Exogenous Parathyroid Hormone in Its Management. Journal of Bone Metabolism 27:1, pages 1.
Crossref
Emiko Ifuku, Takeshi Yoshimura, Toyonobu Uzawa & Tadami Hokonohara. (2019) Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk. Osteoporosis and Sarcopenia 5:2, pages 44-50.
Crossref
Jordi Bover, Pablo Ureña-Torres, Ana María Laiz Alonso, Josep-Vicens Torregrosa, Minerva Rodríguez-García, Cristina Castro-Alonso, José Luis Górriz, Silvia Benito, Víctor López-Báez, María Jesús Lloret Cora, Secundino Cigarrán, Iara DaSilva, Maya Sánchez-Bayá, Silvia Mateu Escudero, Lluis Guirado & Jorge Cannata-Andía. (2019) Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications. Nefrología (English Edition) 39:3, pages 227-242.
Crossref
Jordi Bover, Pablo Ureña-Torres, Ana María Laiz Alonso, Josep-Vicens Torregrosa, Minerva Rodríguez-García, Cristina Castro-Alonso, José Luis Górriz, Silvia Benito, Víctor López-Báez, María Jesús Lloret Cora, Secundino Cigarrán, Iara DaSilva, Maya Sánchez-Bayá, Silvia Mateu Escudero, Lluis Guirado & Jorge Cannata-Andía. (2019) Osteoporosis, densidad mineral ósea y complejo CKD-MBD (II): implicaciones terapéuticas. Nefrología 39:3, pages 227-242.
Crossref
Stuart M. Sprague. 2019. Endocrine Disorders in Kidney Disease. Endocrine Disorders in Kidney Disease 231 242 .
Jordi Bover, Lucía Bailone, Víctor López-Báez, Silvia Benito, Paola Ciceri, Andrea Galassi & Mario Cozzolino. (2017) Osteoporosis, bone mineral density and CKD–MBD: treatment considerations. Journal of Nephrology 30:5, pages 677-687.
Crossref
Young-Eun Park, David S Musson, Dorit Naot & Jillian Cornish. (2017) Cell–cell communication in bone development and whole-body homeostasis and pharmacological avenues for bone disorders. Current Opinion in Pharmacology 34, pages 21-35.
Crossref